Total Raised

$156.25M

Investors Count

16

Deal Terms

3

Funding, Valuation & Revenue

12 Fundings

Veran Medical Technologies has raised $156.25M over 12 rounds.

Veran Medical Technologies's latest funding round was a Acquired for on December 4, 2020.

Veran Medical Technologies's latest post-money valuation is from December 2020.

Sign up for a free demo to see Veran Medical Technologies's valuations in December 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/4/2020

Acquired

$XXM

0

FY undefined

5

12/19/2018

Line of Credit

$35M

$XXM

0

FY undefined

1

11/13/2018

Corporate Minority

$20M

$XXM

0

FY undefined

3

12/21/2016

Series F

$XXM

0

FY undefined

10

12/21/2016

Debt - II

$XXM

$XXM

0

FY undefined

10

Date

12/4/2020

12/19/2018

11/13/2018

12/21/2016

12/21/2016

Round

Acquired

Line of Credit

Corporate Minority

Series F

Debt - II

Amount

$35M

$20M

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

5

1

3

10

10

Start free trial
New call-to-action

Veran Medical Technologies Deal Terms

3 Deal Terms

Veran Medical Technologies's deal structure is available for 3 funding rounds, including their Acquired from December 04, 2020.

Round

Acquired

Series B - II

Series B

Funding Date

$XXM

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

$XXM

Amount Raised

$XXM

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$XXM

$XXM

$XXM

$XXM

Series B - II

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

Veran Medical Technologies Investors

16 Investors

Veran Medical Technologies has 16 investors. Olympus invested in Veran Medical Technologies's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

12/4/2020

12/4/2020

1
Acquired

Corporation

Japan

12/19/2018

12/19/2018

1
Line of Credit

Private Equity

New York

11/13/2018

11/13/2018

1
Corporate Minority

Corporation

United Kingdom

00/00/0000

00/00/0000

RC Capital

Subscribe to see more

Growth Equity

Ohio

00/00/0000

00/00/0000

Versant Ventures

Subscribe to see more

Venture Capital

California

First funding

12/4/2020

12/19/2018

11/13/2018

00/00/0000

00/00/0000

Last Funding

12/4/2020

12/19/2018

11/13/2018

00/00/0000

00/00/0000

Investor

RC Capital

Versant Ventures

Rounds

1
Acquired
1
Line of Credit
1
Corporate Minority

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Private Equity

Corporation

Growth Equity

Venture Capital

Location

Japan

New York

United Kingdom

Ohio

California

New call-to-action

Compare Veran Medical Technologies to Competitors

CIVCO Medical Solutions Logo
CIVCO Medical Solutions

CIVCO Medical Solutions is involved in medical technology related to ultrasound products and services. The company provides products such as ultrasound probe covers, cleaning and disinfection systems, needle guides, and solutions for transperineal prostate procedures. CIVCO's technology aims to address infection control, enhance imaging procedures, and assist during ultrasound interventions. It is based in Kalona, Iowa.

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

R
RadioTherapeutics

RadioTherapeutics Corporation is developing tools for minimally invasive treatment of solid tumors. The RF 2000B is used by surgeons, interventional radiologists, and gastroenterologists to predictably, precisely and homogeneously ablate diseased or unwanted volumes of soft tissues.

B
Biopsys Medical

News of a breast biopsy raises many emotions and concerns. The company understand. But it's important to remember that 80% of breast biopsies do not turn out to be breast cancer. It's also important to know that users have options when selecting a biopsy procedure. This site is dedicated to evaluating their choices to help users talk with their doctor about the breast biopsy procedure that is right for users. One of those choices is a minimally invasive breast biopsy for breast cancer diagnosis using the Mammotome Breast Biopsy System. Mammotome is made available by Ethicon Endo-Surgery, Inc.

B
Biospiral

BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.

T
Tomophase

Tomophase Corporation was founded with the mission of developing solutions for minimally invasive diagnostic (MID) imaging. The company is using light to guide new ways of diagnosing diseases and has conceived major ideas for an optical MID imaging system

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.